Department of Neurosurgery; University of California at San Francisco (UCSF) San Francisco, CA, USA.
Department of Neurosurgery; Warren Alpert Medical School of Brown University Providence, RI, USA.
Expert Rev Endocrinol Metab. 2022 Jul;17(4):293-304. doi: 10.1080/17446651.2022.2082942. Epub 2022 Jun 14.
Pituitary adenomas are a common and diverse group of intracranial tumors arising from the anterior pituitary that are usually slow-growing and benign, but still pose a significant healthcare burden to patients. Additionally, they are increasing in both incidence and prevalence, leading to a need for better understanding of molecular changes in the development of these tumors.
A PubMed literature search was conducted using the terms 'pituitary adenoma' in combination with keywords related to secretory subtype: lactotroph, somatotroph, corticotroph, gonadotroph and null cell, in addition to their transcription factor expression: PIT1, TPIT, and SF-1. Articles resulting from this search were analyzed, as well as relevant articles cited as their references. In this review, we highlight recent advances in the genetic and epigenetic characterization of individual pituitary adenoma subtypes and the effect it may have on guiding future clinical treatment of these tumors.
Understanding the molecular biology of pituitary adenomas is a fundamental step toward advancing the treatment of these tumors. Yet crucial knowledge gaps exist in our understanding of the underlying molecular biology of pituitary adenomas which can potentially be addressed by turning to differentially activated molecular pathways in tumor relative to normal gland.
垂体腺瘤是一种常见且多样化的颅内肿瘤,起源于垂体前叶,通常生长缓慢且为良性,但仍对患者的健康造成重大负担。此外,它们的发病率和患病率都在增加,因此需要更好地了解这些肿瘤发生过程中的分子变化。
使用术语“垂体腺瘤”结合与分泌亚型相关的关键词(催乳素细胞、生长激素细胞、促肾上腺皮质激素细胞、促性腺激素细胞和无分泌细胞),以及它们的转录因子表达(PIT1、TPIT 和 SF-1),在 PubMed 上进行了文献检索。对由此产生的文章进行了分析,并参考了其中引用的相关文章。在这篇综述中,我们强调了个体垂体腺瘤亚型的遗传和表观遗传特征的最新进展,以及这可能对指导这些肿瘤未来的临床治疗产生的影响。
了解垂体腺瘤的分子生物学是推进这些肿瘤治疗的基本步骤。然而,我们对垂体腺瘤潜在分子生物学的理解存在关键的知识空白,通过研究肿瘤相对于正常腺体中差异激活的分子途径,有可能解决这些空白。